Table 1.
Incidence of tardive dyskinesia (TD) for specific antipsychotics
| Mean raw TD incidence | Mean annualized TD incidence | |||||
|---|---|---|---|---|---|---|
| Antipsychotic | N. studies/treatment arms | N. subjects | % | 95% CI | % | 95% CI |
| FGAs | ||||||
| Perphenazine | 1 | 853 | 3.3 | 0.5‐17.4 | 3.7 | 0.1‐6.7 |
| Molindone | 1 | 20 | 2.4 | 0.1‐38.5 | 4.2 | −0.8 to 16.5 |
| Haloperidol | 22 | 2,975 | 6.6 | 4.5‐9.6 | 7.5 | 5.9‐9.2 |
| Chlorpromazine | 1 | 80 | 21.3 | 4.4‐60.1 | 11.2 | 4.8‐17.7 |
| Fluphenazine | 1 | 28 | 3.6 | 3.0‐32.8 | 12.5 | 12.3‐37.3 |
| SGAs | ||||||
| Aripiprazole | 3 | 1,215 | 0.9 | 0.3‐3.1 | 1.7 | −0.8 to 4.1 |
| Amisulpride | 3 | 558 | 1.5 | 0.4‐5.4 | 2.4 | −0.4 to 5.2 |
| Asenapine | 4 | 1,472 | 1.2 | 0.5‐3.3 | 2.4 | −0.1 to 4.8 |
| Risperidone | 20 | 853 | 4.2 | 2.6‐6.6 | 2.4 | 1.2‐3.5 |
| Quetiapine | 6 | 221 | 2.8 | 0.2‐1.1 | 2.5 | 0.2‐4.8 |
| Olanzapine | 29 | 5,686 | 2.7 | 1.9‐4.0 | 2.9 | 1.8‐3.9 |
| Ziprasidone | 7 | 918 | 3.5 | 1.6‐7.5 | 3.5 | 1.3‐5.7 |
| Clozapine | 6 | 348 | 8.2 | 3.9‐16.6 | 4.2 | 1.7‐6.7 |
| Lurasidone | 1 | 427 | 2.6 | 0.5‐13.1 | 4.8 | −0.2 to 9.3 |
The TD rates for the individual medications are not directly comparable, as they do not originate from randomized trials in which those medications were compared head‐to‐head, but are pooled irrespective of study comparators. FGAs – first‐generation antipsychotics, SGAs – second‐generation antipsychotics